Skip to main content
Clinical Trials/NCT02537704
NCT02537704
Unknown
Not Applicable

Translational Study for Overweight and Obesity Management in Adults Using the "Group Lifestyle Balance Program" in Primary Care Clinics and Public Hospitals From Sonora, México

Universidad de Sonora5 sites in 1 country258 target enrollmentSeptember 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Obesity
Sponsor
Universidad de Sonora
Enrollment
258
Locations
5
Primary Endpoint
Change in body weight
Last Updated
9 years ago

Overview

Brief Summary

Obesity is the main modifiable risk factor for the development of chronic diseases in Mexico. Several randomized controlled trials have shown that intensive lifestyle programs are efficacious for the management of obesity. These programs include frequent sessions (14 or more contacts in the first 6 months) focused on diet and physical activity and use a behavior change protocol. In Mexico most primary care clinics and public hospitals apply traditional treatments for obesity management, which have limited effect on weight loss. This study would provide scientific evidence for an effective model for obesity management. Objective. The purpose of this study is to evaluate the effectiveness of the "Group Lifestyle Balance Program" for overweight and obesity management in adults, in primary care clinics and public hospitals from Sonora. This is a translational clinical study. Healthcare providers from the participating clinics will be trained with the Group Lifestyle Balance Program before its implementation. The primary outcome measurement is the change in body weight from baseline to 6 months and 12 months. Changes in body mass index, waist circumference, systolic and diastolic blood pressure, depression, quality of life and stress scales will be measured in patients receiving the program before and 6 and 12 months after starting the program. Additionally, biochemical parameters (fasting glucose, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, fasting insulin, Homeostatic Model Assessment- Insulin Resistance (HOMA-IR) and liver enzymes [Aspartate transaminase (AST), Alanine Aminotransferase (ALT)] will be evaluated from baseline to 12 months.

Registry
clinicaltrials.gov
Start Date
September 2015
End Date
April 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rolando Giovanni Díaz Zavala

Professor (Full).

Universidad de Sonora

Eligibility Criteria

Inclusion Criteria

  • Adults (\>18 years of age and \<65)
  • Overweight or Obese (BMI \>25 kg/m2 y \<50 kg/m2)
  • Availability and motivation to attend the intervention program
  • Patients who would benefit from participating in the program according to the health providers
  • Signing an informed consent

Exclusion Criteria

  • Medical conditions affecting body weight significantly
  • Pregnancy or nursing
  • Bariatric surgery
  • Being unable to participate in regular moderate physical activity
  • Blood pressure \>160 mm/Hg

Outcomes

Primary Outcomes

Change in body weight

Time Frame: Change in body weight from baseline to 6 months and change in body weight from baseline to 12 months

Secondary Outcomes

  • Change in HDL-cholesterol(Change in HDL-cholesterol from baseline to 12 months)
  • Change in triglycerides(Change in triglycerides from baseline to 12 months)
  • Change in liver enzymes [AST and ALT](Change in liver enzymes [AST and ALT] from baseline to 12 months)
  • Change in the Beck Depression Inventory score(Change in the Beck Depression Inventory score from baseline to 6 months and change in in the Beck Depression Inventory score from baseline to 12 months)
  • Change in total cholesterol(Change in total colesterol from baseline to 12 months)
  • Change in fasting insulin(Change in fasting insulin from baseline to 12 months)
  • Change in the Short Form-36 Health Survey score(Change in the Short Form-36 Health Survey score from baseline to 6 months and change in the SF-36 Health Survey score from baseline to 12 months)
  • Change in fasting glucose(Change in fasting glucose from baseline to 12 months)
  • Change in HOMA-IR(Change in HOMA-IR from baseline to 12 months)
  • Change in waist circumference(Change in waist circumference from baseline to 6 months and change in waist circumference from baseline to 12 months)
  • Change in body fat percentage(Change in body fat percentage from baseline to 6 months and change in body fat percentage from baseline to 12 months)
  • Change in the Perceived Stress Scale (PSS) -14 score(Change in the Perceived Stress Scale (PSS) -14 score from baseline to 6 months and change in the Perceived Stress Scale PSS-14 score from baseline to 12 months)
  • Change in systolic and diastolic blood pressure(Change in systolic and diastolic blood pressure from baseline to 6 months and change in systolic and diastolic blood pressure from baseline to 12 months)
  • Change in LDL-cholesterol(Change in LDL-cholesterol from baseline to 12 months)

Study Sites (5)

Loading locations...

Similar Trials